Galera Therapeutics, Inc. (GRTX)

1.6200 -0.1200 (-6.90%) At close: 04:00PM EDT

Galera Therapeutics, Inc.

2 West Liberty Boulevard
Suite 100
Malvern, PA 19355
United States
610 725 1500
https://www.galeratx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 30

Key executives

Name	Title	Pay	Exercised	Year born
Dr. J. Mel Sorensen M.D.	CEO, Pres & Director	820.77k	N/A	1957
Mr. Christopher Degnan	Chief Financial Officer	529.35k	N/A	1980
Mr. Mark J. Bachleda M.B.A., Pharm.D.	Chief Commercial Officer	476.5k	N/A	1975
Dr. Robert A. Beardsley M.B.A., Ph.D.	Co-Founder & COO	N/A	N/A	1962
Dr. Dennis P. Riley Ph.D.	Chief Scientific Officer, Emeritus	N/A	N/A	N/A
Ms. Jennifer Evans Stacey Esq.	Chief Legal & Compliance Officer and Sec.	N/A	N/A	1965
Dr. Jon T. Holmlund M.D.	Chief Medical Officer	N/A	N/A	1957
Ms. Andie Collier	Sr. VP of Regulatory Affairs	N/A	N/A	N/A
Ms. Judy Schnyder	Sr. VP of Clinical Operations & Data Management	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Corporate governance

Galera Therapeutics, Inc.’s ISS governance QualityScore as of 1 May 2022 is 7. The pillar scores are Audit: 1; Board: 8; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.